Literature DB >> 16682759

Trisomy 18 in neonates: prenatal diagnosis, clinical features, therapeutic dilemmas and outcome.

Barbara Goc1, Zofia Walencka, Agata Włoch, Ewa Wojciechowska, Danuta Wiecek-Włodarska, Joanna Krzystolik-Ładzińska, Klaudiusz Bober, Janusz Swietliński.   

Abstract

The study aimed to analyse the clinical courses of aggressively treated neonates with cytogenetically confirmed trisomy 18, with special attention focused on the efficiency of prenatal diagnostics, associated malformations, therapeutic dilemmas and outcomes. We investigated retrospectively the data concerning 20 neonates with trisomy 18, admitted to the Neonatal Intensive Care Unit (NICU) in Katowice between January 2000 and February 2005. Their birth weights ranged from 650 g to 2400 g, mean 1812 g; gestational age ranged from 27 to 42 weeks, median 38 weeks. Intrauterine growth retardation was noticed in 90% of neonates. Trisomy 18 was suspected prenatally in 40% of cases. Most (80%) of newborns were delivered by caesarean section (92% of neonates with prenatally unrecognized chromosomal defects, 62% of neonates with trisomy 18 suspicion) and 70% of infants needed respiratory support immediately after birth. Cardiac defects were present in 95%, central nervous system malformations in 65%, severe anomalies of digestive system or abdominal wall in 25% of patients. Nine surgical operations were performed during hospitalization (4 were palliative cardiac surgeries). Six patients (30%) survived the neonatal period and were discharged from the NICU. The median survival of the neonates who died was 20 days. In 4 cases cardiac problems implicated their death; in others, deaths were attributed to multiorgan failure, prematurity and/or infection. Further improvement of efficiency of prenatal ultrasound screening for diagnosis of trisomy 18 in the fetus is necessary. A lack of prenatal diagnosis of trisomy 18 in the fetus results in a high rate of unnecessary caesarean sections in these pregnancies. Despite the aggressive treatment most neonates with trisomy 18 died during the neonatal period. The majority of deaths were attributed to cardiorespiratory and multiorgan failure. Concerning the poor prognosis, prompt karyotyping (using FISH) of clinically suspected trisomy 18 is very important, because many invasive procedures and surgeries may then be avoided.

Entities:  

Mesh:

Year:  2006        PMID: 16682759     DOI: 10.1007/BF03194617

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  15 in total

1.  Ultrasound detection and perinatal outcome of fetal trisomies 21, 18 and 13 in the absence of a routine fetal anomaly scan or biochemical screening.

Authors:  C J Moran; J B Tay; J J Morrison
Journal:  Ultrasound Obstet Gynecol       Date:  2002-11       Impact factor: 7.299

2.  Natural history of trisomy 18.

Authors:  N D Embleton; J P Wyllie; M J Wright; J Burn; S Hunter
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

Review 3.  Ultrasound screening for fetal abnormalities.

Authors:  L S Chitty
Journal:  Prenat Diagn       Date:  1995-12       Impact factor: 3.050

4.  Population-based analyses of mortality in trisomy 13 and trisomy 18.

Authors:  Sonja A Rasmussen; Lee-Yang C Wong; Quanhe Yang; Kristin M May; J M Friedman
Journal:  Pediatrics       Date:  2003-04       Impact factor: 7.124

5.  Survival in trisomy 18.

Authors:  S Root; J C Carey
Journal:  Am J Med Genet       Date:  1994-01-15

6.  Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.

Authors:  K H Nicolaides; G Azar; D Byrne; C Mansur; K Marks
Journal:  BMJ       Date:  1992-04-04

7.  Avoidance of emergency surgery in newborn infants with trisomy 18.

Authors:  A P Bos; C J Broers; F W Hazebroek; J O van Hemel; D Tibboel; E Wesby-van Swaay; J C Molenaar
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

8.  Natural history of trisomy 18 and trisomy 13: I. Growth, physical assessment, medical histories, survival, and recurrence risk.

Authors:  B J Baty; B L Blackburn; J C Carey
Journal:  Am J Med Genet       Date:  1994-01-15

9.  Clinical experience with trisomies 18 and 13.

Authors:  M E Hodes; J Cole; C G Palmer; T Reed
Journal:  J Med Genet       Date:  1978-02       Impact factor: 6.318

10.  Detection of chromosomal abnormalities, an outcome of ultrasound screening. The Eurofetus Team.

Authors:  H Grandjean; D Larroque; S Levi
Journal:  Ann N Y Acad Sci       Date:  1998-06-18       Impact factor: 5.691

View more
  5 in total

1.  Patient characteristics associated with in-hospital mortality in children following tracheotomy.

Authors:  Jay G Berry; Robert J Graham; David W Roberson; Lawrence Rhein; Dionne A Graham; Jing Zhou; Jane O'Brien; Heather Putney; Donald A Goldmann
Journal:  Arch Dis Child       Date:  2010-06-03       Impact factor: 3.791

2.  Long-Term Outcomes of Children With Trisomy 13 and 18 After Congenital Heart Disease Interventions.

Authors:  Jennifer K Peterson; Lazaros K Kochilas; Kirsti G Catton; James H Moller; Shaun P Setty
Journal:  Ann Thorac Surg       Date:  2017-04-26       Impact factor: 4.330

3.  Predictors of clinical outcomes and hospital resource use of children after tracheotomy.

Authors:  Jay G Berry; Dionne A Graham; Robert J Graham; Jing Zhou; Heather L Putney; Jane E O'Brien; David W Roberson; Don A Goldmann
Journal:  Pediatrics       Date:  2009-07-13       Impact factor: 7.124

4.  22q11.2 distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome.

Authors:  Shay Ben-Shachar; Zhishuo Ou; Chad A Shaw; John W Belmont; Millan S Patel; Marybeth Hummel; Stephen Amato; Nicole Tartaglia; Jonathan Berg; V Reid Sutton; Seema R Lalani; A Craig Chinault; Sau W Cheung; James R Lupski; Ankita Patel
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

5.  Cardiac surgery in patients with trisomy 18.

Authors:  Yukihiro Kaneko; Jotaro Kobayashi; Ikuya Achiwa; Hitoshi Yoda; Keiji Tsuchiya; Yayohi Nakajima; Daiichi Endo; Hajime Sato; Tadashi Kawakami
Journal:  Pediatr Cardiol       Date:  2009-04-02       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.